Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GoFintech Quantum Innovation Limited
國富量子創新有限公司

(formerly known as GoFintech Innovation Limited 國富創新有限公司)
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 290)
Website: https://290.com.hk

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board (the "**Board**") of directors (the "**Directors**") of GoFintech Quantum Innovation Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that during a meeting of the Board held on 14 August 2025, Dr. Liang Jinxiang ("**Dr. Liang**") has been appointed as an independent non-executive Director and a member of each of the audit committee of the Board, the remuneration committee of the Board and the nomination committee of the Board with effect from 14 August 2025.

The biographical details of Dr. Liang are set out as follows:

Dr. Liang, aged 41, obtained a master's degree in business administration from Yunnan University of Finance and Economics in 2016, and further obtained a Ph.D. in international studies (economics) from Dong-A University in 2025. Dr. Liang has been focused on finance and capital markets and has more than 15 years of experience in investment and mergers and acquisitions, corporate risk control and financial audit management. He has led various large-scale mergers and acquisitions and capital operation projects and has a systematic practical operation and theoretical research foundation in financial and tax compliance management.

Dr. Liang has a solid theoretical foundation and rich practical experience, his research areas cover financial and tax compliance, behavioral economics and corporate risk management. Dr. Liang has professional qualifications and technical capabilities in information system auditing, IT risk control, IT governance and information security; he has technical expertise and governance capabilities in the field of financial technology and is a Certified Information Systems Auditor ("**CISA**"). In recent years, Dr. Liang has presided over and/or participated in a number of National Natural Science Foundation projects and has been deeply involved in cutting-edge research on financial technology and risk management. Dr. Liang is currently a visiting professor at a number of universities, executive dean of Shenzhen Yuncai Management Science Research Institute, president of Shenzhen Yunnan University of Finance and Economics Alumni Association (the "**Alumni Association**") and chairman of the Fund Investment Committee of the Alumni Association. Dr. Liang has served as director of risk control and investment committee member of

several domestic investment group companies. Dr. Liang has been an independent non-executive director of Zhong Jia Guo Xin Holdings Company Limited (a company listed on the main board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), stock code: 899) since 2 April 2025.

The Company has entered into a letter of appointment with Dr. Liang for an initial term of twelve (12) months with effect from the date of his appointment subject to the terms of renewal contained therein and retirement by rotation and re-election in accordance with the articles of association of the Company. Dr. Liang will hold office until the next annual general meeting of the Company and be eligible for re-election at the meeting. Dr. Liang is entitled to a remuneration of HK$180,000 per annum which was determined and approved by the remuneration committee of the Board and the Board with reference to his duties, work experience, responsibilities, the Company's performance as well as the prevailing market conditions.

Dr. Liang has confirmed his independence with regards to each of the factors referred to in Rule 3.13(1) to (8) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"). It has also been confirmed that (i) Dr. Liang has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined in the Listing Rules) of the Company; and (ii) there are no other factors that might affect his independence at the time of his appointment.

Save as disclosed in this announcement and as at the date of this announcement, Dr. Liang (i) does not have any interest in the shares of the Company (the "**Shares**") or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationships with any Directors, senior management, substantial or controlling shareholders of the Company (as defined under the Listing Rules); (iii) does not hold any other positions in the Group; (iv) has not held any other directorships in any other public companies the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years; (v) does not have any other major appointments and professional qualifications; and (vi) is not aware of any other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules or any other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Dr. Liang on his new appointments.

By order of the Board of
GoFintech Quantum Innovation Limited
CHAN Kin Sang
Chairman and Independent Non-executive Director

Hong Kong, 14 August 2025

As at the date of this announcement, the Board consists of one executive Director, namely Ms. SUN Qing; three non-executive Directors, namely Dr. NIE Riming, Mr. LI Chunguang and Mr. HUA Yang; and four independent non-executive Directors, namely Mr. CHAN Kin Sang (Chairman), Mr. CHIU Kung Chik, Ms. LUI Mei Ka and Dr. Liang Jinxiang.